Nabriva Therapeutics, Vizient Inks Xenleta Distribution Pact

Nabriva Therapeutics Plc NBRV entered an agreement with Vizient to offer Xenleta as a contracted product to Vizient's Pharmacy Network Program.
Xenleta is indicated for community-acquired bacterial pneumonia (CABP).
Vizient offers expertise, analytics and advisory services, and a contract portfolio that represents more than $110 billion in annual purchasing volume to improve patient outcomes and lower costs.
Nabriva CEO Ted Schroeder commented, "We are excited by Vizient's decision to agree to make XENLETA available to their Hospital Pharmacy Network, enabling access across Vizient member hospitals, which make up more than half of U.S. hospitals. Based on data from the Healthcare Cost and Utilization Project, it is estimated that approximately 3 million adults are diagnosed with CABP in the hospital setting annually."
Price Action: NBRV stock is up 0.85% at $1.12 during the market session on the last check Thursday.